Back to Blog
Idarucizumab dose7/8/2023 There are no known significant interactions.The safety and effectiveness of repeat treatment with idarucizumab have not been established.Plasma dabigatran concentrations can increase more than 12-24 hours after idarucizumab administration, likely due to re-distribution from the extravascular compartment.Idarucizumab will likely correct aPTT and plasma-dilute thrombin time, but the correlation of lab results with improved outcomes is not established.Monitor for signs/symptoms of clinically relevant bleeding and thromboembolic events.Prior to use, assess the presence of dabigatran using elevated thrombin time as the marker for anticoagulant effect.Life-threatening or uncontrolled bleedingĪ humanized monoclonal antibody fragment that binds dabigatran to neutralize its anticoagulant effects as measured by plasma-dilute thrombin time.No other infusion should be administered in parallel via the same intravenous access.Īpproved for reversal of the anticoagulant effect of dabigatran in the setting of:.The line must be flushed with sterile 0.9% Sodium Chloride Injection, USP solution prior to infusion. A pre-existing intravenous line may be used for administration of idarucizumab.Idarucizumab must be administered within 1 hour after removal from the vials.Infusion of each 2.5gm vial should take no longer than 5-10 minutes the second vial must be administered within 15 minutes of the first vial.The recommended dose of idarucizumab (Praxibind) is 5 g intravenously, administered in two 2.5gm doses, no more than 15 minutes apart.
0 Comments
Read More
Leave a Reply. |